Bli medlem
Bli medlem

Du är här


AstraZeneca: AstraZeneca to collaborate with the University of Michigan to advance treatments for chronic kidney disease

AstraZeneca today announced a two-year research collaboration with the
University of Michigan to advance the treatment of chronic kidney
disease (CKD) through the improved understanding of the disease. The
collaboration will tackle the challenging area of identifying novel
targets for the treatment of CKD, focusing on the use of patient
tissue and validation of preclinical models.

CKD is a condition in which the kidneys are damaged and cannot filter
blood effectively, leading to waste from the blood remaining in the
body, which may cause other health problems such as cardiovascular
disease, heart attack or stroke. Most patients progress eventually to
end-stage renal disease and require haemodialysis and kidney

Under the terms of the collaboration, scientists from AstraZeneca's
laboratories in Mölndal, Sweden, will work with a team of
investigators at the University of Michigan led by Matthias Kretzler,
Professor of Internal Medicine and Computational Medicine and
Bioinformatics to:

· examine databases of biopsies from CKD patients to identify
biological targets and pathways which predict disease progression

· create improved animal models that better reflect the human
disease condition

· identify biomarkers in patient samples which are associated with
disease progression and response to treatment

Marcus Schindler, Head of the Cardiovascular and Metabolic Diseases
(CVMD) Innovative Medicines Unit, AstraZeneca, said: "Current
approaches to treating the complications of diabetes mean that
patients need expensive treatment options which are often limited, so
there is a significant unmet medical need. Through this
collaboration, we will generate increasing evidence that we are
pursuing the right therapeutic targets to treat CKD which will shift
clinical therapy to a more focused patient population, giving a
better response to treatments and slowing disease progression."

Matthias Kretzler said: "The collaboration builds on the promise of
combining basic university research, which can uncover specific
targets for precise-acting drugs, with drug compound development by
AstraZeneca. Steered by science, we will examine new approaches to
treating the damage that diabetes inflicts on the kidneys of millions
of people."

- ENDS -


About the University of Michigan

The University of Michigan Health System creates the future of health
care through medical education, patient care and research. UMHS is a
community of more than 26,000 faculty, staff, trainees and
volunteers, including 3 hospitals and 40 outpatient locations. The
University of Michigan Medical School consistently ranks among the
top research universities in the United States and world. With one of
the nation's largest research budgets, The University of Michigan
finds new ways to understand, diagnose, treat, manage and prevent
many human diseases.

About AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business
that focuses on the discovery, development and commercialisation of
prescription medicines, primarily for the treatment of
cardiovascular, metabolic, respiratory, inflammation, autoimmune,
oncology, infection and neuroscience diseases. AstraZeneca operates
in over 100 countries and its innovative medicines are used by
millions of patients worldwide. For more information please visit:


Media Enquiries

Karen Birmingham +44 20 7604 8120 (UK/Global)

Esra Erkal-Paler +44 20 7604 8030 (UK/Global)


Författare WKR

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.